Novo Historical Income Statement

NVO Stock

USD 106.13 1.57 1.50%

Historical analysis of Novo Nordisk income statement accounts such as Total Revenue of 243.9 B can show how well Novo Nordisk AS performed in making a profits. Evaluating Novo Nordisk income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Novo Nordisk's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Novo Nordisk AS latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novo Nordisk AS is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

About Novo Income Statement Analysis

Novo Nordisk AS Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Novo Nordisk shareholders. The income statement also shows Novo investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Novo Nordisk Income Statement Chart

At this time, Novo Nordisk's EBIT is very stable compared to the past year. As of the 29th of November 2024, EBITDA is likely to grow to about 120.4 B, while Interest Expense is likely to drop about 429.4 M.

Selling General Administrative Total Revenue Other Operating Expenses

Total Revenue

Total revenue comprises all receipts Novo Nordisk AS generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Novo Nordisk AS. It is also known as Novo Nordisk overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Novo Nordisk's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Novo Nordisk AS current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

	2021	2022	2023	2024 (projected)
Gross Profit	117.1B	148.5B	196.5B	206.3B
Total Revenue	140.8B	177.0B	232.3B	243.9B

Gross Profit Total Revenue

Novo Nordisk income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling And Marketing Expenses	Net Income From Continuing Ops	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.09	0.69	0.82	0.82	0.82	0.81	0.78	0.82	0.83	0.82	0.81	0.17	0.81	0.82	0.86	0.69	0.71	0.74	-0.33	0.58	0.79
Interest Expense	0.09		0.06	0.03	0.03	0.0	0.06	0.04	0.04	0.0	0.0	0.01	-0.46	0.02	-0.01	-0.01	0.05	-0.24	-0.1	0.22	-0.02	-0.08
Selling General Administrative	0.69	0.06		0.93	0.93	0.94	0.92	0.92	0.92	0.93	0.94	0.92	0.1	0.92	0.92	0.91	0.62	0.79	0.54	-0.55	0.45	0.61
Total Revenue	0.82	0.03	0.93		1.0	1.0	1.0	0.99	1.0	1.0	1.0	0.99	0.13	0.99	0.99	0.99	0.83	0.91	0.79	-0.64	0.51	0.83
Gross Profit	0.82	0.03	0.93	1.0		1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.12	1.0	0.99	0.99	0.83	0.91	0.79	-0.64	0.51	0.83
Other Operating Expenses	0.82	0.0	0.94	1.0	1.0		0.99	0.99	0.99	1.0	1.0	0.99	0.14	0.99	0.99	0.99	0.83	0.9	0.79	-0.62	0.5	0.83
Operating Income	0.81	0.06	0.92	1.0	1.0	0.99		1.0	1.0	0.99	0.99	1.0	0.11	1.0	0.99	0.98	0.83	0.91	0.79	-0.65	0.52	0.82
Ebit	0.78	0.04	0.92	0.99	1.0	0.99	1.0		1.0	0.99	0.98	1.0	0.11	1.0	0.99	0.98	0.83	0.92	0.78	-0.66	0.5	0.82
Ebitda	0.82	0.04	0.92	1.0	1.0	0.99	1.0	1.0		0.99	0.99	1.0	0.12	1.0	0.99	0.98	0.83	0.91	0.8	-0.64	0.52	0.83
Cost Of Revenue	0.83	0.0	0.93	1.0	1.0	1.0	0.99	0.99	0.99		1.0	0.99	0.13	0.99	0.98	0.98	0.84	0.91	0.79	-0.63	0.48	0.85
Total Operating Expenses	0.82	0.0	0.94	1.0	1.0	1.0	0.99	0.98	0.99	1.0		0.99	0.14	0.99	0.99	0.99	0.83	0.9	0.78	-0.62	0.51	0.82
Income Before Tax	0.81	0.01	0.92	0.99	1.0	0.99	1.0	1.0	1.0	0.99	0.99		0.19	1.0	1.0	0.99	0.82	0.92	0.8	-0.65	0.57	0.82
Total Other Income Expense Net	0.17	-0.46	0.1	0.13	0.12	0.14	0.11	0.11	0.12	0.13	0.14	0.19		0.19	0.22	0.19	-0.05	0.31	0.25	-0.15	0.67	0.07
Net Income	0.81	0.02	0.92	0.99	1.0	0.99	1.0	1.0	1.0	0.99	0.99	1.0	0.19		1.0	0.99	0.82	0.93	0.8	-0.65	0.56	0.82
Income Tax Expense	0.82	-0.01	0.92	0.99	0.99	0.99	0.99	0.99	0.99	0.98	0.99	1.0	0.22	1.0		0.99	0.8	0.92	0.8	-0.63	0.59	0.8
Research Development	0.86	-0.01	0.91	0.99	0.99	0.99	0.98	0.98	0.98	0.98	0.99	0.99	0.19	0.99	0.99		0.81	0.91	0.81	-0.58	0.6	0.82
Selling And Marketing Expenses	0.69	0.05	0.62	0.83	0.83	0.83	0.83	0.83	0.83	0.84	0.83	0.82	-0.05	0.82	0.8	0.81		0.79	0.9	-0.65	0.25	0.91
Net Income From Continuing Ops	0.71	-0.24	0.79	0.91	0.91	0.9	0.91	0.92	0.91	0.91	0.9	0.92	0.31	0.93	0.92	0.91	0.79		0.79	-0.77	0.47	0.83
Tax Provision	0.74	-0.1	0.54	0.79	0.79	0.79	0.79	0.78	0.8	0.79	0.78	0.8	0.25	0.8	0.8	0.81	0.9	0.79		-0.53	0.55	0.9
Interest Income	-0.33	0.22	-0.55	-0.64	-0.64	-0.62	-0.65	-0.66	-0.64	-0.63	-0.62	-0.65	-0.15	-0.65	-0.63	-0.58	-0.65	-0.77	-0.53		-0.11	-0.56
Net Interest Income	0.58	-0.02	0.45	0.51	0.51	0.5	0.52	0.5	0.52	0.48	0.51	0.57	0.67	0.56	0.59	0.6	0.25	0.47	0.55	-0.11		0.3
Reconciled Depreciation	0.79	-0.08	0.61	0.83	0.83	0.83	0.82	0.82	0.83	0.85	0.82	0.82	0.07	0.82	0.8	0.82	0.91	0.83	0.9	-0.56	0.3

Click cells to compare fundamentals

Novo Nordisk Account Relationship Matchups

Novo Nordisk income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	171.9K	5.3B	5.3B	6.6B	9.4B	9.9B
Interest Expense	220M	390M	2.5B	378M	542M	429.4M
Selling General Administrative	4.0B	4.0B	4.1B	4.5B	4.9B	6.5B
Total Revenue	122.0B	126.9B	140.8B	177.0B	232.3B	243.9B
Gross Profit	101.9B	106.0B	117.1B	148.5B	196.5B	206.3B
Other Operating Expenses	69.5B	72.8B	82.2B	102.1B	129.7B	136.2B
Operating Income	52.5B	54.1B	58.6B	74.8B	102.6B	107.7B
Ebit	57.8B	54.0B	60.1B	75.4B	105.2B	110.5B
Ebitda	57.8B	59.3B	65.4B	82.0B	114.6B	120.4B
Cost Of Revenue	20.1B	20.9B	23.7B	28.4B	35.8B	37.6B
Total Operating Expenses	49.5B	51.9B	58.5B	73.7B	93.9B	98.6B
Income Before Tax	48.6B	53.1B	59.1B	69.1B	104.7B	109.9B
Total Other Income Expense Net	(3.9B)	(996M)	436M	(5.7B)	2.1B	2.2B
Net Income	39.0B	42.1B	47.8B	55.5B	83.7B	87.9B
Income Tax Expense	9.6B	11.0B	11.3B	13.5B	21.0B	22.0B
Research Development	14.2B	15.5B	17.8B	24.0B	32.4B	34.1B
Net Income Applicable To Common Shares	39.0B	42.1B	47.8B	55.5B	63.9B	67.0B
Selling And Marketing Expenses	31.8B	32.9B	37.0B	46.2B	56.7B	32.3B
Net Income From Continuing Ops	39.0B	42.1B	47.8B	55.5B	83.7B	87.9B
Tax Provision	9.6B	11.0B	11.3B	13.5B	21.0B	12.8B
Interest Income	3.8B	337M	558M	239M	1.1B	1.2B
Net Interest Income	(436M)	(203M)	(180M)	(320M)	330M	346.5M
Reconciled Depreciation	5.7B	5.8B	6.0B	7.4B	9.4B	6.5B

Pair Trading with Novo Nordisk

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.

Moving together with Novo Stock

0.76	HLN	Haleon plc	Pair Corr
0.86	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.74	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.8	ANRO	Alto Neuroscience,	Pair Corr

Moving against Novo Stock

0.85	AXP	American Express Fiscal Year End 24th of January 2025	Pair Corr
0.76	TRV	The Travelers Companies Fiscal Year End 17th of January 2025	Pair Corr
0.72	FNMFO	Federal National Mortgage Upward Rally	Pair Corr
0.58	KB	KB Financial Group	Pair Corr
0.5	ITCL	Banco Ita Chile	Pair Corr

The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.

The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:

How To Invest In Novo

Details

Is Novo Stock a good investment?

Details

What is Novo Nordisk's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.224

Dividend Share

9.9

Earnings Share

2.99

Revenue Per Share

60.698

Quarterly Revenue Growth

0.214

The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novo Historical Income Statement

About Novo Income Statement Analysis

Novo Nordisk Income Statement Chart

Total Revenue

Other Operating Expenses

Novo Nordisk income statement Correlations

Novo Nordisk Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novo Nordisk income statement Accounts

Pair Trading with Novo Nordisk

Moving together with Novo Stock

Moving against Novo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Other Operating Expenses	+ 1.0	Total Revenue
Operating Income	+ 1.0	Total Revenue
Ebitda	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Total Revenue

Interest Income	- 0.77	Net Income From Continuing Ops
Interest Income	- 0.66	Ebit
Interest Income	- 0.65	Selling And Marketing Expenses
Interest Income	- 0.65	Net Income
Interest Income	- 0.65	Income Before Tax
Interest Income	- 0.65	Operating Income